Race Oncology Ltd RAC
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- A$1.82
- Day Range
- A$1.76–1.82
- 52-Week Range
- A$0.65–2.09
- Bid/Ask
- A$1.76 / A$1.78
- Market Cap
- A$302.50 Mil
- Volume/Avg
- 74,406 / 128,311
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
Race Oncology Ltd is a clinical stage biopharmaceutical company with a mission to be at the heart of cancer care. Its asset, bisantrene, is a small molecule chemotherapeutic. Bisantrene has a clinical history with demonstrated therapeutic benefits in both adult and paediatric patients, a well characterised safety profile, and compelling clinical data demonstrating an anticancer effect and less cardiotoxicity over certain anthracyclines, such as doxorubicin. It has reformulated bisantrene (RC220) to address the high unmet needs of patients across multiple oncology indications, with a clinical focus on anthracycline combinations, where Race can deliver cardioprotection and enhanced anticancer activity in solid tumours.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Core
- Total Number of Employees
- —
- Website
- https://www.raceoncology.com
Comparables
Valuation
|
Metric
|
RAC
|
IMU
|
NUVL
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | 16.51 | 2.97 | 10.07 |
Price/Sales | — | — | — |
Price/Cash Flow | — | — | — |
Price/Earnings
RAC
IMU
NUVL
Financial Strength
|
Metric
|
RAC
|
IMU
|
NUVL
|
|---|---|---|---|
Quick Ratio | 27.86 | 3.66 | 17.23 |
Current Ratio | 28.36 | 3.86 | 17.44 |
Interest Coverage | — | −321.34 | — |
Quick Ratio
RAC
IMU
NUVL
Profitability
|
Metric
|
RAC
|
IMU
|
NUVL
|
|---|---|---|---|
Return on Assets (Normalized) | — | −67.09% | −23.36% |
Return on Equity (Normalized) | — | −77.26% | −24.62% |
Return on Invested Capital (Normalized) | — | −79.58% | −28.80% |
Return on Assets
RAC
IMU
NUVL
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Novo Nordisk AS ADR
NVO
| Jjrxryqlt | Ynpm | $531.4 Bil | |||
| Vertex Pharmaceuticals Inc
VRTX
| Zkrhvgf | Hhfrlc | $119.5 Bil | |||
| Regeneron Pharmaceuticals Inc
REGN
| Wmttjtml | Jdtjx | $114.9 Bil | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Kgwmyjtr | Fgsnzy | $35.3 Bil | |||
| argenx SE ADR
ARGX
| Nxsjskfs | Ysgj | $32.0 Bil | |||
| BioNTech SE ADR
BNTX
| Znblgwrrd | Mljch | $28.1 Bil | |||
| Moderna Inc
MRNA
| Gmgmrng | Gqqb | $25.3 Bil | |||
| United Therapeutics Corp
UTHR
| Mfhfyqkwf | Khjx | $16.0 Bil | |||
| Biomarin Pharmaceutical Inc
BMRN
| Lmqpcznq | Jfmfbdm | $13.4 Bil | |||
| Incyte Corp
INCY
| Mqycmvrw | Zdkjrt | $12.7 Bil |
United States